BioNTech, Pfizer initiate rolling submission to EMA for SARS-CoV-2 vaccine candidate

This article was originally published here

The EMA’s decision to start a rolling review follows the encouraging preliminary results from pre-clinical and early clinical studies in adults, which suggest that BNT162b2 triggers the production

The post BioNTech, Pfizer initiate rolling submission to EMA for SARS-CoV-2 vaccine candidate appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply